EHA 2023 | Phase I/II study of bosutinib in newly diagnosed & resistant/intolerant pediatric patients with CML

Erica Brivio • 10 Jun 2023

EHA 2023

ITCC-054/COG-AAML1921

Erica Brivio, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, comments on the results of a Phase I/II study evaluating bosutinib in pediatric patients with newly diagnosed and resistant/intolerant chronic myeloid leukemia (CML; NCT04258943). The study reported an efficacy that was similar to that of other second-generation tyrosine kinase inhibitors (TKIs), with a safety profile similar to what is observed in adults. The most common adverse event was gastrointestinal (GI) toxicity. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.